donepezil has been researched along with Deficiency, Mental in 2 studies
Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.
donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " A 38-year-old woman with Down syndrome, diagnosed with secondary progressive dementia when her mental state had deteriorated rapidly after graduation from junior high school, started donepezil treatment." | 7.73 | Dramatic improvement in Down syndrome-associated cognitive impairment with donepezil. ( Aikawa, K; Amamoto, N; Aoki, M; Doi, T; Hamada, H; Harada, J; Kondoh, T; Moriuchi, H; Nakashima, M; Ogawa, Y; Sasaki, H; Tanaka, T, 2005) |
| " A 38-year-old woman with Down syndrome, diagnosed with secondary progressive dementia when her mental state had deteriorated rapidly after graduation from junior high school, started donepezil treatment." | 3.73 | Dramatic improvement in Down syndrome-associated cognitive impairment with donepezil. ( Aikawa, K; Amamoto, N; Aoki, M; Doi, T; Hamada, H; Harada, J; Kondoh, T; Moriuchi, H; Nakashima, M; Ogawa, Y; Sasaki, H; Tanaka, T, 2005) |
| "Whereas Trisomy 21 is one of the most widespread genetic causes of intellectual disability (ID), it still is one of the least understood of all genetic ID syndromes." | 2.49 | Atypical aging in Down syndrome. ( Zigman, WB, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zigman, WB | 1 |
| Kondoh, T | 1 |
| Amamoto, N | 1 |
| Doi, T | 1 |
| Hamada, H | 1 |
| Ogawa, Y | 1 |
| Nakashima, M | 1 |
| Sasaki, H | 1 |
| Aikawa, K | 1 |
| Tanaka, T | 1 |
| Aoki, M | 1 |
| Harada, J | 1 |
| Moriuchi, H | 1 |
1 review available for donepezil and Deficiency, Mental
| Article | Year |
|---|---|
Atypical aging in Down syndrome.
Topics: Adult; Aging; Alzheimer Disease; Amyloid beta-Peptides; Cholinesterase Inhibitors; Dementia; Donepez | 2013 |
1 other study available for donepezil and Deficiency, Mental
| Article | Year |
|---|---|
Dramatic improvement in Down syndrome-associated cognitive impairment with donepezil.
Topics: Adult; Cholinesterase Inhibitors; Cognition Disorders; Dementia; Donepezil; Down Syndrome; Female; H | 2005 |